BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it will showcase its recently FDA cleared Omnipod DASHTM Insulin Management System (Omnipod DASH System), during the American Diabetes Association (ADA) 78th Scientific Sessions at the Orange County Convention Center in Orlando, Florida June 22-25, 2018. Insulet will also have a robust clinical presence at the meeting with 10 accepted abstracts, including six posters and three oral presentations.
Insulet’s largest presence to date will feature its new, innovative Omnipod DASH System in a product theater, a variety of hands-on, interactive product demonstrations, and other events during the show and at its exhibit booth (#1603). The Company will also present new research results for its innovation pipeline, including the Omnipod Horizon™ Automated Glucose Control (Omnipod Horizon) System and the use of concentrated insulin in the Omnipod System, as well as additional data further supporting the benefits of the Omnipod System. For the second consecutive year, Omnipod Horizon System research was selected to be highlighted in the official ADA Press Program based upon its overall excellence in furthering research and advancing treatment for people with diabetes.
“This is truly an exciting time for Insulet,” said Shacey Petrovic, President and Chief Operating Officer. “We are committed to delivering innovative new products to the diabetes community with the upcoming launch of our new Omnipod DASH System. We are also pleased to present new research demonstrating the significant progress we are making on our robust innovation roadmap.”
A schedule of Insulet clinical presentations at ADA is as follows:
| Time | Presentation | Location | ||||
| Saturday June 23 | ||||||
| 8:15 – 8:30 AM |
65-OR Reducing basal insulin 90 minutes before exercise protects against hypoglycemia better than insulin suspension at exercise onset in T1D: The OmniTIME Results
Dessi Zaharieva, Sarah M. McGaugh, Rubin Pooni, Todd Vienneau, Trang T. Ly, Michael Riddell |
Oral Presentation – W204 | ||||
| 11:30 AM – 12:30 PM |
1695-P Reduced Rate of Acute Complications with Tubeless Insulin Pump Use: Data from 2,640 Patients in the German/Austrian DPV Registry
Torben Biester, Thomas Danne, Esther Bollow, Anke Schwandt, Bettina Heidtmann, Birgit Rami-Merhar, Thomas Haak, Reinhard W. Holl |
Poster Hall | ||||
| 11:30 AM – 12:30 PM |
1011-P Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with T2D: the VIVID Study—Primary Population
George Grunberger, Anuj Bhargava, Trang T. Ly, Howard Zisser, Liza Ilag, James K. Malone, Shuyu Zhang, Jennal Johnson |
Poster Hall | ||||
| 11:30 AM – 12:30 PM |
1038-P Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements
Xiaosu Ma, Randy P. Prescilla, Shuyu Zhang, Helle Linnebjerg, Linda Morrow, Jeffrey A. Jackson, Jennal Johnson, Derek Leishman |
Poster Hall | ||||
| Sunday June 24 | ||||||
| 12:00 – 1:00 PM |
967-P Patient Reported Outcomes (PRO) in a Study of Human Regular U-500 Insulin (U-500R) Delivered by Continuous Subcutaneous Insulin Infusion (CSII) or Multiple Daily Injections (MDI) in Patients with T2D
Xiaomei Peng, Jieling Chen, Ludi Fan, Liza Ilag, Trang T. Ly, Jennal Johnson |
Poster Hall | ||||
| 2:30 – 2:45 PM |
207-OR Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adults with Type 1 Diabetes Over Five Days Under Free-Living Conditions
Bruce A. Buckingham, Jennifer L. Sherr, Gregory P. Forlenza, Thomas A. Peyser, Joon Bok Lee, Jason B. O’Connor, Bonnie Dumais, Lauren M. Huyett, Jennifer E. Layne, Trang T. Ly |
Oral Presentation – W308 | ||||
| Monday June 25 | ||||||
| 12:00 – 1:00 PM |
1376-P Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adolescents with Type 1 Diabetes Over Five Days Under Free-Living Conditions
Gregory P. Forlenza, Bruce A. Buckingham, Jennifer L. Sherr, Thomas A. Peyser, Joon Bok Lee, Jason B. O’Connor, Bonnie Dumais, Lauren M. Huyett, Jennifer E. Layne, Trang T. Ly |
Poster Hall | ||||
| 12:00 – 1:00 PM |
1377-P Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Children with Type 1 Diabetes Over Five Days Under Free-Living Conditions
Jennifer L. Sherr, Gregory P. Forlenza, Bruce A. Buckingham, Thomas A. Peyser, Joon Bok Lee, Jason B. O’Connor, Bonnie Dumais, Lauren M. Huyett, Jennifer E. Layne, Trang T. Ly |
Poster Hall | ||||
| 5:45 – 6:00 PM |
351-OR Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with T2D: the VIVID Study—All Randomized Population
George Grunberger, Anuj Bhargava, Trang T. Ly, Howard Zisser, Liza Ilag, James K. Malone, Shuyu Zhang, Jennal Johnson |
Oral Presentation – W415D (Valencia Ballroom) | ||||
| Additional Abstracts | ||||||
| Published abstract |
2274-PUB Long-term Use of Omnipod® Insulin Management System Associated with Lower A1c in Adults with Established Diabetes and A1c ≥8%
Liane J. Tinsley, Lori M. Laffel, Zijing Guo, Nisha Naik, Jennifer E. Layne, Trang T. Ly, Sanjeev N. Mehta |
|||||
1 The Pod has a waterproof IPX8 rating for up to 25 feet for 60 minutes. The PDM is not waterproof.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and www.omnipodeurope.com.*
*Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it already does in the United States and Canada.
Forward-Looking Statement:
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 22, 2018 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
© 2018 Insulet Corporation. DASH, Horizon, Omnipod and the Omnipod logo are trademarks or registered trademarks of Insulet Corporation. All rights reserved. The Bluetooth® word mark and logos are registered trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Insulet Corporation is under license.
